Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
05 April 2024 - 11:00PM
Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us”
or the “Company”), a clinical-stage biotechnology company
addressing serious diseases with significant unmet need, today
announces that its abstract has been accepted for the 2024 American
Society of Clinical Oncology (ASCO) meeting on May 31 through June
4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local
administration of pembrolizumab for treatment of bladder cancer: A
novel strategy to minimize toxicity” will be published at
www.asco.org/abstracts.
Dr. Jonathan Kaufman, Chief Executive Officer of
Lipella, said, “ASCO’s 2024 meeting is the ideal venue for
dissemination of our recent progress in the treatment of bladder
cancer. Lipella’s new product candidate, LP-50 (intravesical
pembrolizumab), is intended to be indicated for non-muscle invasive
bladder cancer (NMIBC). Our abstract includes preclinical data
demonstrating the efficacy of intravesical pembrolizumab in mice,
including size-reduction in bladder tumors measured via T2 weighted
MRI.”
ASCO is the world's leading professional
organization for physicians and oncology professionals caring for
people with cancer. Its annual meeting is the most significant
gathering of oncology professionals worldwide, and aims to change
the landscape of cancer care.
Dr. Michael Chancellor, Lipella’s Chief Medical
Officer, emphasized the significance of this milestone for
advancing the company’s LP-50 program. He stated, “There exists a
critical unmet need for patients with non-muscle invasive bladder
cancer. Our proprietary liposomal drug delivery technology enables
localized delivery of therapeutics such as pembrolizumab, which can
have severe adverse effects when absorbed systemically.”
About LP-50
LP-50 is an intravesical formulation of
immunoglobulins including local, intravesical PD-1 (i.e.
checkpoint) inhibition, intended for the treatment of non-muscle
invasive bladder cancer (NMIBC), offering the potential for
increasing efficacy while minimizing systemic toxicity.
About Lipella Pharmaceuticals
Inc.
Lipella Pharmaceuticals is a clinical-stage
biotechnology company focused on developing new drugs by
reformulating the active agents in existing generic drugs and
optimizing these reformulations for new applications. Additionally,
Lipella maintains a therapeutic focus on diseases with significant,
unaddressed morbidity and mortality where no approved drug therapy
currently exists. Lipella completed its initial public offering in
December 2022. For more information, please visit www.lipella.com
or LinkedIn.
Forward-Looking Statements
This press release includes certain
"forward-looking statements." All statements, other than statements
of historical fact, included in this press release regarding, among
other things, our strategy, future operations, financial position,
prospects, clinical trials, regulatory approvals, pipeline and
opportunities, sources of growth, successful implementation of our
proprietary technology, plans and objectives are forward-looking
statements. Forward-looking statements can be identified by words
such as "may," "will," "could," "continue," "would," "should,"
"potential," "target," "goal," "anticipates," "intends," "plans,"
"seeks," "believes," "estimates," "predicts," "expects," "projects"
and similar references to future periods. Forward-looking
statements are based on our current expectations and assumptions
regarding future events and financial trends that we believe may
affect among other things, market and other conditions, our
financial condition, results of operations, business strategy,
short- and long-term business operations and objectives, and
financial needs. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. We caution you, therefore, against
relying on any of these forward-looking statements. They are
neither statements of historical fact nor guarantees or assurances
of future performance. There are risks, uncertainties and other
factors, both known and unknown, that could cause actual results to
differ materially from those in the forward-looking statements
which include, but are not limited to, risks related to the
effective application of the use of proceeds from the private
placement, general capital market risks, regional, national or
global political, economic, business, competitive, market and
regulatory conditions, and other factors. Any forward-looking
statement made by us is based upon the reasonable judgment of our
management at the time such statement is made and speaks only as of
the date on which it is made. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We undertake no
obligation to update any forward-looking statement, whether as a
result of new information, future developments or otherwise, except
as may be required by applicable law. Nothing contained herein is,
or shall be relied upon as, a promise or representation as to the
past or future. In addition, the information contained in this
press release is as of the date hereof, and the Company has no
obligation to update such information, including in the event that
such information becomes inaccurate. You should not construe the
contents of this press release as legal, tax and financial advisors
as to legal and related matters concerning the matters described
herein.
CONTACTDr. Jonathan Kaufman, CEOLipella
PharmaceuticalsInfo@Lipella.com 1-412-894-1853
PCG AdvisoryJeff
Ramsonjramson@pcgadvisory.com
Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From Apr 2024 to May 2024
Lipella Pharmaceuticals (NASDAQ:LIPO)
Historical Stock Chart
From May 2023 to May 2024